The goals focus on clinical and regulatory progress against its five mid- to late-stage programs, including patisiran, which is advancing toward potential global regulatory approvals and commercialization, paving the way for the Company to achieve its Alnylam 2020 goals.
January 7, 2018
· 10 min read
